SynthesisHuman genetics2026
Gene-based association analysis of depression risk among European ancestry Parkinson's disease patients.
Synthesis in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Depression is one of the most common and disabling non-motor symptoms in Parkinson's disease (PD), yet its genetic basis remains poorly understood. Here, we investigate the genetic contributions to depression in PD by estimating the burden from common as well as low-frequency single nucleotide polymorphisms (SNPs) within genes previously implicated in PD or depression risk among European ancestry PD patients from three population-based studies. Using gene-based association analyses (SKAT, Burden, and SKAT-O) in the PASIDA, PEG, and PPMI studies, we evaluated SNP sets in gene regions previously linked to PD or depression. Among PD-related genes, meta-analysis identified a significant association between KRTCAP2 and self-reported depression diagnosis in PD (SKAT-O p = 4.33 × 10⁻⁵), which remained significant after false discovery rate correction. A higher genetic burden in KRTCAP2 was associated with 20% increased odds of depression (OR = 1.20, 95% CI: 1.04-1.38). TRAF5 and LRRK2 showed marginal associations. Among depression-related genes, SPPL3 and ERBB4 were associated with depression diagnosis history, and FNIP2 was associated with current depressive symptoms. The PD polygenic risk score was not associated with depression in PD, while a higher depression polygenic risk score was significantly associated with increased odds of depression diagnosis in both cohorts and the meta-analysis (OR = 1.26, 95% CI: 1.13-1.40). Our findings highlight immune-related genes such as KRTCAP2 and TRAF5 as potential contributors to depression in PD. Additionally, the depression PRS shows statistically significant association with depression diagnosis in PD, suggesting that a general depression-related genetic liability contributes to this non-motor feature in PD. Together, these results suggest that depression in PD may involve both shared and disease-specific genetic mechanisms, offering new insights into its pathogenesis and potential therapeutic targets.
Indexed as
Identifiers
42888321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.